ERBB2 and breast carcinoma: This inverse association remained only for HR+/HER2− breast cancer incidence among NHW women (per‐quartile RR = 0.92, 95% CI 0.87–0.96, p = 0.00079), HR+/HER2+ (per‐quartile RR = 0.89, 95% CI 0.80–0.98, p = 0.024), TN (per‐quartile RR = 0.90, 95% CI 0.82–0.97, p = 0.010), and marginally for HR+/HER2− (per‐quartile RR = 0.93, 95% CI 0.88–1.01, p = 0.056) breast cancer incidence among NHB women.